Blood levels of glial fibrillary acidic protein (GFAP), a marker for neuroinflammation, have shown potential in differentiating AD from FTD and predicting the progression from MCI to AD dementia (Cicognola et al., 2021; Oeckl et al., 2022). Here, GFAP is linked to frontotemporal dementia.